FH Healthcare Consulting provides services to Life Sciences organizations helping them optimize theirmarket access and reimbursement, leveragingHEOR tools: that is,achievable price, time to market and patient population size.
Its Founder and Managing Director, Andrea Latour, has a unique blend ofstrategy & commercial,market access & pricing, andHEOR & evidence generation experience, from many years in Industry and Consulting roles, across European and APAC markets.
| Type | Assignment | Client / Year |
|---|---|---|
| Market access, pricing and policy | Pricing analysis for new launch in mantle cell lymphoma based on NICE analogues and IRP | Large Pharma, 2015 |
| Market access, pricing and policy | KOL and patient org mapping and engagement in collaboration with MAF, and stakeholder input to NICE appraisal for key asset in MCL | Large Pharma, 2015 |
| Market access, pricing and policy | Pricing strategy and access schemes option identification for new product in CLL in Australia (PBAC) | Large Pharma, 2016-2017 |
| Market access, pricing and policy | Analysis of achievable price for key asset in CLL, in reference to SOC, new assets, analogues and precedents, and IRP, in Australia | Large Pharma, 2017-2018 |
| Market access, pricing and policy | Quantifying affording population in South-Asian markets for ultra-high, high and medium price medicines, and identifying key applicable public, private and alternative funding mechanisms | Med-size Pharma, 2020 |
| Market access, pricing and policy | KOL mapping and engagement recommendations for minimal residual disease (MRD) in haematology in Australia and Japan | Small/Mid-size Pharma 2020 |
| Market access, pricing and policy | Access pathway mapping for genome testing in NICU patients with rare genetic diseases, in Japan | Mid-size MedTech, 2020 |
| Market access, pricing and policy | White paper on key issues and policy developments in access to high-cost oncology medicines in developed markets and in Asia | Large Pharma, 2020 |
| Market access, pricing and policy | PharEast Conference - Panel: Adapting to the changing market access landscape | PharEast Conference, 2021 |
| Market access, pricing and policy | Challanges and delays in access in mood disorders compared to other TAs globally and recommendations to improve access | Large Pharma, 2021 |
| Market access, pricing and policy | Mapping optimal pathways for regulatory and market access for biomarker-based technologies in mood disorders in Australia, China, Japan, Korea and Taiwan | Large Pharma, 2021 |
| Market access, pricing and policy | Mapping opportunity for launch in private markets, in terms of market size and maturity, across 40 countries and for partnership with private health insurance providers, ex-US | Large Pharma, 2021 |
| Market access, pricing and policy | Landscaping and assessment of bridging strategies for CV outcomes trials and implications to P&R - Playbook and Position paper | Large Pharma, 2022 |
| Market access, pricing and policy | Workshop on opportunities for partnership with private health insurance, after scoping for alternative funding mechanisms | Large Pharma, 2024 |
| Health economics | CEM and BIM adaptation for atorvastatin in Italy | Large Pharma, 2009-2010 |
| Health economics | CEM (Core Diabetes Model) country adaptations and technical reports (European markets) in T2DM | Large Pharma, 2010-2011 |
| Health economics | Development of global CEA and BI models for product in metastatic melanoma, incl survival analysis | Large Pharma, 2011-2013 |
| Health economics | CEA and BI global model adaptation for product in metastatic melanoma - Spain | Large Pharma, 2012-2013 |
| Health economics | BI model development for product in adjuvant melanoma - Sweden | Large Pharma, 2012-2013 |
| Health economics | Budget impact models for NICE and SMC submissions for new treatment in COPD | Large Pharma/MedTech, 2011-2012 |
| Health economics | SLR for SMBG in T2DM, incl search strategy design, search execution, abstract/full-text review and data extraction | Large Pharma/MedTech 2012 |
| Health economics | SLR and CEM development for product in wet age-related macular degeneration | Large Pharma, 2012 |
| Health economics | CEM for new product launch in NASH focusing on hepatic and CV events | Mid-size Pharma, 2012-2013 |
| Health economics | CEM and BOI model adaptations for new long-acting injectable in schizophrenia in the UK | Large Pharma, 2013 |
| Health economics | CMA of new fixed-dose combination in HIV compared to single agents and SOC in Scotland and Wales | Large Pharma, 2013 |
| Health economics | CEM development and ITC/MAIC for major new asset in mantle cell lymphoma, for NICE submission | Large Pharma, 2014-2015 |
| Health economics | Visiting lecturer to Cambridge uni MSC students on CEA and BIA | Cambridge uni, 2015 |
| Health economics | CEA for new product vs SOC, incl companion diagnostics, in CLL in Australia | Large Pharma, 2016-2017 |
| Health economics | CMA for new product vs Key comparator targeted therapy, with different MOA and treatment duration, in CLL, in Australia | Large Pharma, 2017-2018 |
| Health economics | Outcomes-based BIM adaptation and value proposition development for TAVI in APAC markets | Large MedTech, 2018 |
| Health economics | CEM and BIM model adaptations for Transarterial Radio embolization in HCC, in APAC markets | Mid-size MedTech, 2019 |
| Health economics | Budget impact analysis and cost-based value proposition for CAR-T + publication, in Singapore | Large Pharma, 2019 |
| Health economics | Model adaptations for a new asset in neuroendocrine tumours in Taiwan, Korea, Hong Kong and Singapore | Large Pharma, 2019-2020 |
| Health economics | Cost of illness model development in haemophilia A, focusing on prophylaxis and treatment of bleed events, in APAC markets | Large Pharma, 2019-2020 |
| Health economics | CEM adaptation for prostate cancer drug in Taiwan | Large Pharma, 2020 |
| Health economics | Targeted lit review, KOL interviews and CEM & BIM adaptation for product in CKD in Indonesia | Large Pharma, 2020 |
| Health economics | CEM re-development for genome testing in NICU patients with rare genetic diseases, in Japan | Mid-size MedTech, 2020 |
| Health economics | CEM development for different management options for malaria in Uganda | Large Pharma/MedTech 2020 |
| Health economics | CMA and BIA for introduction of new vaccine in Middle-East markets | Large Pharma, 2020 |
| Health economics | ISPOR presentation: Uniqueness and challenges of economic evaluations in oncology. Drugs, devices and diagnostics | ISPOR oral presentation, 2020 |
| Health economics | ISPOR presentation: Modelling oncology from patient-level data: parametric models and extrapolations | ISPOR oral presentation, 2020 |
| Health economics | Pragmatic CEM development to support value proposition of reduced resource consumption with bleed prophylaxis | Large Pharma, 2020-2021 |
| Health economics | Model adaptations and reports for innovative product in wound care in APAC markets, incl SEA | Mid-size MedTech, 2020-2021 |
| Health economics | Model adaptation for new PARP inhibitor in ovarian cancer in Singapore | Large Pharma, 2021 |
| Health economics | Commercial forecasting and budget impact analysis for a new CAR-T incl sequential algorithm and cannibalization, in Australia, China and Japan | Large Pharma, 2022 |
| HTA | BIA section of NICE submission for product in wet age-related macular degeneration | Large Pharma, 2012 |
| HTA | HTA submission for new formulation of existing products (various) in HIV - SMC Scotland and AWMSG Wales | Large Pharma, 2013-2014 |
| HTA | HTA submission for new fixed dose combination in HIV - SMC Scotland and AWMSG Wales | Large Pharma, 2013-2014 |
| HTA | HTA submission for major blockbuster launch in mantle cell lymphoma - NICE England | Large Pharma, 2015-2016 |
| HTA | HTA submission for major launch in chronic lymphocytic leukaemia, submission and re-submissions - PBAC Australia | Large Pharma, 2016-2018 |
| HTA | HTA strategy and dossier writing for Transarterial Radio embolization in HCC, in Korea and Taiwan | Mid-size MedTech, 2019 |
| HTA | HTA strategy and execution for a new asset in neuroendocrine tumours in Taiwan, Korea, Hong Kong and Singapore | Large Pharma, 2019-2020 |
| HTA | Led the negotiation process between the Agency for Care Effectiveness (ACE) and The Singapore Association of Pharmaceutical Industries (SAPI) for the development of the new manufacturer-led HTA submission process | ACE and SAPI, 2020 |
| HTA | ACE submissions for PD-L1 inhibitor in two indications, incl model adaptation and targeted lit review | Large Pharma, 2022 |
| Outcomes research / RWE | Research and compilation of observational evidence to support value proposition of atorvastatin for regional access in Italy | Large Pharma, 2009-2010 |
| Outcomes research / RWE | Costing study for resource utilisation to manage spasticity in multiple sclerosis, incl publication | Large Pharma, 2011 |
| Outcomes research / RWE | Integrated evidence generation planning as part of cross-functional international team, for new asset and new indications in haematology | Large Pharma, 2017-2018 |
| Outcomes research / RWE | Review of 14 early compounds across TAs for probability of success, on behalf of A*STAR for the Singapore Therapeutic Development Review process | Singapore government entity, 2020 |
| Outcomes research / RWE | Competitive TPP assessment, clinical and economic evidence gaps analysis for two gene therapies in ophthalmology in Australia, Japan, China and Korea | Large Pharma, 2021 |
| Outcomes research / RWE | Quality of evidence and gap analysis for new asset in SCLC cancer in APAC markets | Large Pharma, 2021 |
| Outcomes research / RWE | Evidence gaps assessment and strategy for tumour agnostic innovative medicine in Japan | Large Pharma, 2021 |
| Outcomes research / RWE | Market access risks & opportunities based on evidence-gap assessment in SCCHN cancer in China, Japan, Australia, Korea and Taiwan | Large Pharma, 2022 |
| Outcomes research / RWE | Market access risks & opportunities based on evidence-gap assessment in SCLC cancer in China, Japan, Australia and Korea | Large Pharma, 2022 |
| Commercial & Strategy | Asia Healthcare conference Panel session: Future of healthcare in Asia | Asia Healthcare conference, 2021 |
| Commercial & Strategy | Commercial due diligence for Pharma co acquisition across all TAs in SEA markets | Large PE firm, 2021 |
| Commercial & Strategy | Design and implementation for restructuring of NPP and CEx functions in APAC | Large Pharma, 2022 |
| Commercial & Strategy | Market entry strategy for conglomerate into Pharma business in Vietnam | Conglomerate |
| Commercial & Strategy | Development of AI-powered 'Patient Intelligence Engine' to predict patient drop-outs and prescribe next-best-action in APAC | Large Pharma, 2023 |
| Commercial & Strategy | AI-driven customer identification, segmentation and reach in fertility, in Taiwan | Mid-size Pharma/Consumer Health, 2023 |
| Commercial & Strategy | Commercial due diligence for likelihood of success of early stage asset in ovarian cancer in Korea | Large Pharma, 2024 |
| Commercial & Strategy | Market entry opportunity assessment (SEA) and manufacturing plant location assessment (Thailand Vs Indonesia) | Small Pharma, 2024 |
| Commercial & Strategy | Product, channel strategy for midsize pharma co across SEA and other Asian markets | Mid-size Pharma, 2024 |
| Commercial & Strategy | Market segmentation and opportunity prioritization on obstructive sleep apnea, in China, Japan and Thailand | Mid-size MedTech, 2024 |
| Type | Name & Info | Link |
|---|---|---|
| Costing study | V Stevenson, A Latour, J Broughton, A Lloyd. Cost of spasticity associated with multiple sclerosis in the UK; presented at the ABN (Association of British Neurologists) Meeting 2011 [J Neurol Neurosurg Psychiatry 2012;83:e1 doi:10.1136/jnnp-2011-301993.192] | Available here |
| HE modelling | Latour A, Schweikert B, Desai M. Reduction in costs over two years when treating with darunavir/ritonavir compared to atazanavir/ritonavir in the UK. ISPOR, Milan 2015. | Available here |
| HE modelling | Iannazzo S, Coco B, Brunetto MR, Rossetti F, Caputo A, Latour A, Espinos B, Bonino F. Individualized treatment of HBeAg-negative CHB using peg-interferon alfa-2a as first-line and week 12 HBV-DNA\HBsAg stopping rule. A cost-effectiveness analysis; published in 'Annuals of Internal Medicine' [PMID: 23486701]. | Available here |
| HE modelling | S Critchlow, D Lee, A Latour, M Wildgust, J Goldberg, S Rule, M Wang. Modelling the Effectiveness of Ibrutinib Versus Rituximab-Based Chemotherapy Regimens in Relapsed/Refractory Mantle Cell Lymphoma. ISPOR, Vienna 2016. | Available here |
| HE modelling | Lakhanpal, Latour, Wang, Wang, Budget IMPACT Analysis (BIA) of Introducing Tisagenlecleucel for the Treatment of Patients with Relapsed and Refractory Diffuse Large B-CELL Lymphoma (R/R DLBCL) in Singapore (SG). ISPOR APAC (Virtual) 2020. | Available here |
FREEDOM HOUSE (FH) - HEALTHCARE CONSULTING PTE. LTD.
133 New Bridge Road #23-09 Chinatown Point, Singapore 059413